Trends in GPCR drug discovery: new agents, targets and indications
G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly
due to their substantial involvement in human pathophysiology and their pharmacological …
due to their substantial involvement in human pathophysiology and their pharmacological …
[HTML][HTML] The locus coeruleus-norepinephrine system in stress and arousal: unraveling historical, current, and future perspectives
JA Ross, EJ Van Bockstaele - Frontiers in psychiatry, 2021 - frontiersin.org
Arousal may be understood on a spectrum, with excessive sleepiness, cognitive dysfunction,
and inattention on one side, a wakeful state in the middle, and hypervigilance, panic, and …
and inattention on one side, a wakeful state in the middle, and hypervigilance, panic, and …
[HTML][HTML] Charge-specific adverse effects of polystyrene nanoplastics on zebrafish (Danio rerio) development and behavior
M Teng, X Zhao, F Wu, C Wang, C Wang… - Environment …, 2022 - Elsevier
Nanoplastics are being detected with increasing frequency in aquatic environments.
Although evidence suggests that nanoplastics can cause overt toxicity to biota across …
Although evidence suggests that nanoplastics can cause overt toxicity to biota across …
Role of FoxO transcription factors in aging and age-related metabolic and neurodegenerative diseases
S Du, H Zheng - Cell & bioscience, 2021 - Springer
Aging happens to all of us as we live. Thanks to the improved living standard and discovery
of life-saving medicines, our life expectancy has increased substantially across the world in …
of life-saving medicines, our life expectancy has increased substantially across the world in …
How cholesterol interacts with membrane proteins: an exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains
J Fantini, FJ Barrantes - Frontiers in physiology, 2013 - frontiersin.org
The plasma membrane of eukaryotic cells contains several types of lipids displaying high
biochemical variability in both their apolar moiety (eg, the acyl chain of glycerolipids) and …
biochemical variability in both their apolar moiety (eg, the acyl chain of glycerolipids) and …
Alzheimer's disease
CL Masters, R Bateman, K Blennow… - Nature reviews disease …, 2015 - nature.com
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20
years) and an average clinical duration of 8–10 years. The disease has an estimated …
years) and an average clinical duration of 8–10 years. The disease has an estimated …
Action of molecular switches in GPCRs-theoretical and experimental studies
G protein coupled receptors (GPCRs), also called 7TM receptors, form a huge superfamily of
membrane proteins that, upon activation by extracellular agonists, pass the signal to the cell …
membrane proteins that, upon activation by extracellular agonists, pass the signal to the cell …
Sexual dimorphism in predisposition to Alzheimer's disease
DW Fisher, DA Bennett, H Dong - Neurobiology of aging, 2018 - Elsevier
Clinical studies indicate that Alzheimer's disease (AD) disproportionately affects women in
both disease prevalence and rate of symptom progression, but the mechanisms underlying …
both disease prevalence and rate of symptom progression, but the mechanisms underlying …
The cholinergic system, the adrenergic system and the neuropathology of Alzheimer's disease
RA Bekdash - International Journal of Molecular Sciences, 2021 - mdpi.com
Neurodegenerative diseases are a major public health problem worldwide with a wide
spectrum of symptoms and physiological effects. It has been long reported that the …
spectrum of symptoms and physiological effects. It has been long reported that the …
The delta opioid receptor: an evolving target for the treatment of brain disorders
AA Pradhan, K Befort, C Nozaki… - Trends in …, 2011 - cell.com
Compared to the better-known mu opioid receptor, delta opioid receptors have been
relatively understudied. However, the development of highly selective delta opioid agonists …
relatively understudied. However, the development of highly selective delta opioid agonists …